Autoimmune/Cholestatic/Biliary Diseases News

The FDA granted orphan drug designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, according to a press release from Krystal Biotech.

Seladelpar reduced serum alkaline phosphatase and bilirubin at 12 months in more than 60% of patients with primary biliary cholangitis compared with 20% of placebo-treated patients, according to manufacturer, CymaBay Therapeutics.

Female surgeons had fewer surgical and total complications in elective and acute care cholecystectomies but longer operating times compared with male surgeons, according to data in JAMA Surgery.

After 3 months of treatment, seladelpar significantly improved pruritus and markers of liver injury compared with placebo in patients with primary biliary cholangitis, CymaBay Therapeutics recently announced.

EASL Congress 2023 has ended but, as the society’s official media partner, Healio was at the forefront covering the latest in liver disease. Wondering what you may have missed? Healio recaps the biggest news disrupting the specialty.

Topline findings from the phase 3 ELATIVE trial showed that elafibranor improved cholestasis response in patients with primary biliary cholangitis, Ipsen and Genfit announced.

In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritus due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress.

The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.

Healio will present its sixth annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.

The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis.